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Obesiteetti eli lihavuus on maailmaa uhkaava sairaus, joka aiheuttaa kasvavia kustannuksia. Obesiteetin, 
jossa painoindeksi eli BMI on yli 30, ja ylipainon, painoindeksi 25–30 välillä, ehkäisemiseksi epigeneettisten 
tekijöiden, kuten miRNA:iden, tunteminen on tärkeää. Lasten Sepelvaltimotaudin Riskitekijät (LASERI) on 
vuonna 1980 aloitettu tutkimus, jonka viimeisimpään 2012 valmistuneeseen seurantaan osallistui 2 063 33–
48-vuotiasta tutkimushenkilöä. Tutkimusaineistossa 22 miRNA:ta oli yhteydessä joko painoindeksiin (BMI) tai 
vyötärö-lantio-suhteeseen riippumatta iästä ja sukupuolesta. 
Varianssianalyysissä (ANOVA) selvisi, että miR-122 ja miR-144 olivat tilastollisesti merkitsevästi 
yhteydessä kehon eri fenotyyppeihin, jotka olivat normaalipainoinen, ylipainoinen tai obeesi. MicroRNA-122:n 
tiedetään olevan sidonnainen maksaan ja verenkierron miR-122-tasojen olevan koholla obeeseilla henkilöillä. 
MicroRNA-144-tasot olivat laskeneet ylipainoisilla. On mahdollista, että miR-144 assosioituu häiriintyneeseen 
glukoosiaineenvaihduntaan. 
MicroRNA-144 saattaa siis olla merkittävä säätelytekijä ylipainon muodostumisessa. Uutena 
löydöksenä tutkimusryhmämme selvitti, että miR-223 oli yhteydessä Activator protein 1 (AP-1) metaboliareittiin 
Gene set enrichment analysis (GSEA) -tutkimuksen mukaan (FDR q-arvo < 0,25). Ylipainoisilla AP-1 
metaboliareitti oli hiljentynyt terveisiin verrattuna. 
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Introduction 
 
 
 
1.1 Background 
 
 
Due to increasing prevalence rate obesity (body mass index, BMI>30) is leading to a public health 
crisis. Overweight, 25<BMI<30, is a simultaneously growing problem. A total of 1.9 billion or 39 % 
of the world’s total population has been estimated to be overweight or obese in 2014 (WHO’s 
statistics 2004 and 2015). Even in developing countries, obesity has grown into pandemic proportions 
and the crisis is worldwide (Wang, Beydoun, Liang, Caballero, & Kumanyika, 2008). Obesity is 
associated with several diseases such as several cancers, metabolic disease, diabetes, cardiovascular 
disease, osteoarthiritis, hypertension and hypercholesterolemia (do Carmo et al., 2016; Duclos, 2016; 
Hall, Crook, Jones, Wofford, & Dubbert, 2002; Hall, do Carmo, da Silva, Wang, & Hall, 2015; 
Mazzarella, 2015; Parhofer, 2015; Vucenik & Stains, 2012; Zimmet, Alberti, & Shaw, 2001). It is 
well-established that overweight would decrease individuals’ life-expectancy by eight years (Grover 
et al., 2015; Ovaskainen et al., 2015). 
Lagos-Quintana et al. describe miRNA formation as follows: “MicroRNAs are transcribed from DNA 
to primary transcripts (pri-miRNA), which are then cleaved to shorter hairpin structures (pre-
miRNAs), exported to cytoplasm, and further processed to form mature one-stranded miRNAs. In 
most cases, miRNAs repress their targets by interaction with the 3’UTR of the target mRNA, inducing 
a detectable change in the mRNA levels.” (Lagos-Quintana, Rauhut, Lendeckel, & Tuschl, 2001.) 
MicroRNAs can also be transported between cells and tissues via circulation. Exogenous miRNA can 
be transported in circulation via microparticles such as exosomes, microvesicles and apoptotic bodies 
(Valadi et al., 2007) or associated with lipoprotein particles (HDL) (Vickers, Palmisano, Shoucri, 
Shamburek, & Remaley, 2011a) or miRNA binding proteins like Argonaute2 (Arroyo et al., 2011) 
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stabilizing their structure. 2588 miRNA have been found in humans (miRBase 21) and it is estimated 
that they would regulate 60% of all genes (Friedman, Farh, Burge, & Bartel, 2009). MicroRNAs can 
be used as diagnostic or prognostic markers. In the future, altering miRNA expression levels could 
be utilized in therapeutics. 
 
1.2 Aims of the study 
 
 
The aim of the study is to find relation between peripheral miRNA expression levels and obesity. 
Finally we briefly try to investigate obesity associated dysregulated metabolic pathways targeted by 
miRNAs. 
 
 
Materials and Methods 
 
 
 
2.1 The Young Finns Study 
 
 
The Cardiovascular Risk in Young Finns Study (YFS) is a large multicenter follow-up study on 
cardiovascular risk from childhood to adulthood. The YFS was launched in 1980, with over 3,500 
children and adolescents (3–18 years old) from all around Finland participating in the baseline study 
(Raitakari et al., 2008). Thereafter the subjects have been followed with several examinations 
including comprehensive risk factor assessments. The 30-year follow-up was performed in 2011–
2012, with 2,063 adults, now aged 33–48 years, participating in the study. The examinations have 
included comprehensive data collection using questionnaires, physical measurements and blood tests. 
The present study has been approved by the Ethical Review Committee of Turku University Hospital. 
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All study subjects have given an informed consent and the study has been conducted according to the 
principles of the Declaration of Helsinki. For the current study, miRNAs were successfully profiled 
from 871 individuals, which were selected on the basis of a) successful RNA isolation, b) availability 
of phenotypic data and c) inclusion in the genome wide gene expression profiling. The demographics 
of the study subpopulation are presented in table 1. (Raitoharju, 2014.) 
 
Table 1. Demographics of the study 
population.   
Amount of subjects 871 
Age, years 43.0 (4.85) 
Female % 54.6 
     
Metabolic syndrome, % 19.4 
Total cholesterol, mmol/l 5.1 (0.91) 
HDL cholesterol, mmol/l 1.3 (0.33) 
LDL cholesterol, mmol/l 3.2 (0.80) 
Triglycerides, mmol 1.1 (0.72) 
     
Diabetes  
Type-1-diabetes, % 0.6 
Type-2-diabetes, % 1.8 
     
Blood glucose 5.3 (0.87) 
     
Blood pressure  
Systolic, mmHg 124.5 (14.7) 
Diastolic, mmHg 76.8 (10.2) 
Body mass index, kg/m2 25.6 (4.9) 
 
2.2 Anthropometry and blood pressure 
 
 
Weight was measured with a Seca weighing scale to the nearest 0.1 kg and height with a Seca 
anthropometer to the nearest centimeter. BMI was calculated as weight(kg)/(height(m))². Waist 
circumference was measured using an anthropometric tape at the midpoint between the iliac crest and 
the lowest rib to the nearest 0.1 cm. The average of two measurements was used. Hip circumference 
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was measured around the widest portion of the buttocks, tape parallel to the floor. Again the average 
of two measurements was used. Waist-to-hip ratio (WHRAT) was calculated waist circumference 
divided by hip circumference. Blood pressure was measured three times after a 5-minute rest with a 
random zero sphygmomanometer. Blood pressure was estimated as the average of the three 
measurements of systolic and diastolic blood pressure. 
 
2.3 Blood samples 
 
 
Venous blood samples were drawn from the right antecubital vein after an overnight fast, and serum 
was separated, aliquoted, and stored at -70°C until analysis. Serum alanine aminotransferase (ALAT), 
aspartate aminotransferase (ASAT), gamma-glutamyltransferase (GT), glucose, cholesterol and 
triglyceride concentrations were measured by enzymatic methods  (ALAT, ASAT, GGT, Glucose, 
Cholesterol and Triglycerides System Reagent, Beckman Coulter Biomedical, Ireland) on an 
automatic analyzer (AU400, Olympus, Japan). Apolipoprotein A1 (ApoA1), apolipoprotein B 
(ApoB) and C-reactive protein (CRP) were determined immunoturbidimetrically (ApoA1 and B 
assay reagent,  Orion Diagnostica, Finland and CRP Latex reagent, Beckman Coulter Biomedical) 
using the same analyzer. The serum triglyceride concentration was assayed using the enzymatic 
glycerol kinase–glycerol phosphate oxidase method (Triglyceride reagent, Beckman Coulter 
Biomedical). Serum total cholesterol levels were measured by the enzymatic cholesterol esterase–
cholesterol oxidase method (Cholesterol reagent, Beckman Coulter Biomedical). The same reagent 
was used for estimating HDL cholesterol levels after the precipitation of LDL and VLDL with dextran 
sulfate- Mg2+. Serum glucose concentrations were determined by the enzymatic hexokinase method 
(Glucose reagent, Beckman Coulter Biomedical). All the above-mentioned assays were performed on 
an AU400 instrument (Olympus). Glycated hemoglobin (GHbA1c) fraction in whole blood was 
measured by an Abbott Architect ci8200 analyzer (Abbott Laboratories). The concentration of total 
5 
 
 
hemoglobin was first determined colorimetrically, after which the concentration of GHbA1c was 
measured immunoturbidimetrically using the microparticle agglutination inhibition method 
(Hemoglobin A1c reagent, Fisher Diagnostics). These two concentrations were used to calculate the 
GHbA1c percentage. (Raitoharju et al., 2014; Suomela et al., 2014.) 
 
2.4 RNA isolation and quality control 
 
 
Whole blood (2.5ml) was collected into PaXgene Blood RNA Tubes (PreAnalytix). The tubes were 
inverted 8–10 times then stored at room temperature for at least 2 hours. The tubes were frozen (-
80°C) and thawed overnight before RNA isolation with a PAXgene Blood microRNA Kit (Qiagen) 
including the DNase Set using the QiaCube. The concentrations and purity of the RNA samples were 
evaluated spectrophotometrically (BioPhotomer, Eppendorf). The RNA isolation process was 
validated by analyzing the integrity of several RNAs with the RNA 6000 Nano Chip Kit (Agilent). 
RNA integrity number (RIN) and the shape of the electropherogram were evaluated. The presence of 
the small RNA fraction was confirmed by the Agilent Small RNA Kit (Agilent). (Raitoharju et al., 
2014.) 
 
2.5 MicroRNA expression profiling 
 
 
MicroRNA expression profiling was performed with the TaqMan® OpenArray® MicroRNA Panel 
(Life Technologies) containing 758 microRNAs, the functionality of which has been previously 
validated with our samples (Raitoharju et al., 2014). Briefly, 100 ng of RNA was used to run both A 
and B pools of Megaplex (Life Technologies) preamplification for cDNA synthesis. In the OpenArray 
Sample Loading Plate, 22.5 µl of each preamplified pool was mixed 1:1 with TaqMan OpenArray 
Real-Time PCR Master Mix. MicroRNA panels were loaded using the AccuFill System and run with 
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the QuantStudio 12K Flex (Life Tehnologies). Original data analysis was performed with Expression 
Suite Software version 1.0.1. RNU6, RNU44 and RNU48 were used as housekeeping small RNAs. 
Principal component analysis was performed in R (http://www.r-project.org/) and data was adjusted 
for 10 principal components. 60 failed samples/outliers were removed. MicroRNAs expressed in at 
least 75% of the samples were included in further analysis. Only assays with Amplification score >1 
and Cq Confidence >0.7 were accepted. (Raitoharju et al., 2016.) 
 
2.6 Genome-wide expression analysis 
 
 
The expression levels were analyzed with an Illumina HumanHT-12 version 4 Expression BeadChip 
(Illumina Inc.) containing 47,231 expression and 770 control probes. In brief, 200 ng of RNA was 
reverse-transcribed into cDNA and biotin-UTP-labeled using the Illumina TotalPrep RNA 
Amplification Kit (Ambion); 1,500 ng of cDNA was then hybridized to the Illumina HumanHT-12 
v4 Expression BeadChip. The BeadChips were scanned with the Illumina iScan system. Raw illumina 
probe data was exported from Beadstudio and analyzed in R (http://www.r-project.org/) using the 
Bioconductor (http://www.bioconductor.org/) packages. The expression data was processed using 
nonparametric background correction, followed by quantile normalization with control and 
expression probes, using the neqc function in the limma package and log2 transformation. The 
expression analysis was successful in 772 of the 908 samples with miRNA expression profile. 
(Raitoharju et al., 2014.) 
 
2.7 Statistical analysis 
 
 
All analyses were performed with SPSS statistics version 22, R-language or bioinformatics tools 
identified below. First we discovered all miRNAs that were related with BMI classes (lean BMI<25, 
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overweight 25≤BMI<30 and obese BMI≥30) below Bonferroni adjusted p-level [i.e. p<0.05/243] 
using one-way analysis of variance, ANOVA, (due to non-gaussian population). MicroRNA levels 
were then correlated with BMI and WHRAT with gaussian correlation (due to abnormal distributions 
as well). Correlations were considered significant if fdr-value < 0.05 (independently of sex and age).  
MicroRNA expression levels were also correlated with metabolite levels and physiological features 
previously associated with metabolic dysfunction (i.e. plasma lipoprotein subclass concentrations, 
glucose and glycosylated hemoglobin levels, branched and aromatic amino acid concentrations, 
anthropometric data, and blood pressure variables) using linear regression model to clarify the 
association between miRNAs and obesity. All phenotypes or physiological features besides 
metabolites that were independently (of sex, age, BMI and WHRAT) associated with obesity related 
with miRNAs (at p<0.05 level) were considered significant. 
Gene set enrichment analysis (GSEA) provided by Broad Institute was conducted to obtain 
differences in miRNA levels between normal and overweight phenotypes (MSigDB database v5.0) 
for those miRNAs that were significantly associated with BMI/WHRAT. Specifically the study 
population was separated into two subgroups by BMI: normal (BMI<25) and overweight (BMI≥25). 
All those predicted mRNA targets that were identified by at least two target predictors (miRecords, 
TarBase, mirTarbase, TargetScan, miRNAorg, Microcosm Targets, PITA, Pictar and miRDB) in 
miRGator v3.0 were included in pathway analysis (Cho et al., 2013). Combining miRNAs’ predicted 
mRNA targets and genome-wide expression data we studied differentially expressed pathways 
between normal and overweight groups. Our analysis included all canonical pathways. Significance 
was predetermined to include all pathways below frd q-value 0.25. 
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Results 
 
 
 
3.1 The miRNA quality control 
 
 
The RNA quality and functionality of the TaqMan OpenArray microRNA expression panels have 
been previously validated (Raitoharju et al., 2014). After quality control and removal of outlier 
miRNA profiling was successful on 871 samples. 772 of these had successful genome wide gene-
expression data available analyzed from the same blood sample/RNA isolation. 276 miRNAs were 
expressed in the whole blood in 75% of the samples and qualified in the further analysis. 
 
3.2 MicroRNAs and obesity 
 
 
A total of 22 miRNAs were associated with either or both BMI and WHRAT (independently of sex 
and age) shown in table 1 below. MicroRNAs 19a-3p, 19b-3p, 144-5p, 25-5p and 106b-3p were 
inversely correlated with BMI. MicroRNAs 122-5p, 23a-3p, 769-5p and 223-3p were directly 
correlated with BMI. Patients were also grouped into lean, overweight and obese individuals and in 
ANOVA miRNA-122 and miRNA-144 were significantly associated with these groups. Results from 
ANOVA analysis can be seen in table 2 below. MicroRNA-122 was found to be directly correlated 
(figure 1) to BMI whereas miRNA-144 (figure 2) had an inverse correlation to BMI. MicroRNA-223 
targeted Activator protein 1 (AP-1) pathway was down-regulated in overweight class (table 3). 
MicroRNAs were also found to be related with sex and miRNAs may regulate different gene 
expressions in opposite sexes. 
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Table 1. Mirna trait results: MicroRNAs that are related to obesity independently of 
sex and age.   
Trait Mirna mirna_p_bon mirna_p_fdr 
bmi 19a-3p 0,030 7,51E-03 
bmi 122-5p 0,064 9,98E-03 
bmi 19b-3p 0,181 1,77E-02 
bmi 144-5p 0,207 1,77E-02 
bmi 25-5p 0,300 1,87E-02 
bmi 106b-3p 0,684 3,80E-02 
bmi 23a-3p 0,905 4,11E-02 
bmi 769-5p 0,894 4,11E-02 
bmi 223-3p 0,864 4,11E-02 
whrat 144-5p 0,000 3,91E-04 
whrat 19b-3p 0,010 5,10E-03 
whrat 103a-3p 0,029 7,51E-03 
whrat 19a-3p 0,070 9,98E-03 
whrat 363-3p 0,068 9,98E-03 
whrat 185-5p 0,099 1,24E-02 
whrat 183-3p 0,230 1,77E-02 
whrat 320a 0,200 1,77E-02 
whrat 1275 0,213 1,77E-02 
whrat 30a-3p 0,270 1,87E-02 
whrat 211-5p 0,289 1,87E-02 
whrat 744-5p 0,334 1,97E-02 
whrat 636 0,738 3,88E-02 
whrat 199a-3p 1,000 4,57E-02 
whrat 1227-3p 1,000 4,63E-02 
whrat 324-5p 1,000 4,84E-02 
 
Table 2. ANOVA. Phenotypes were clustered into three classes due to BMI: lean, overweight and 
obese. Only miRNA-122 and miRNA-144 were significantly associated with these phenotypes. 
MicroRNA Sig. Bonferroni adjusted p-level 
miR-122 8,43E-08 2,03E-05 
miR-144 2,03E-04 0,05 
miR-296 9,25E-04 0,22 
miR-19b 1,17E-03 0,28 
miR-432 1,66E-03 0,40 
miR-142 4,87E-03 1,17 
miR-106b 5,11E-03 1,23 
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Figure 1. MicroRNA-122 levels are elevated in overweight. 
 
Figure 2. MicroRNA-144 profiles are inversely correlated with BMI. 
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Table  3. MicroRNA-223 is associated with AP1 (activator protein 1) pathway in GSEA (Gene 
set enrichment analysis). 
Phenotype Normal versus overweight 
Upregulated in class Normal 
GeneSet AP1-PATHWAY 
Nominal p-value 0.00384 
FDR q-value 0.167 
FWER p-Value 0.089 
Statistically significant (FDR q-value below 0.25 and nominal p-value below 0.05). 
 
3.3 Gene Set Enrichment analysis 
 
 
Combining the predicted miRNA target genes from miRGator v3.0 (genes that were identified by at 
least two databases) and gene expression data we tried to identify all metabolic pathways that would 
be dysregulated in obesity. All predicted or validated target genes that were statistically correlated 
with gene expression data (p<0.05) were taken into Gene set enrichment analysis (GSEA) provided 
by the Broad Institute. GSEA is a computational method that provides information of differences 
between different phenotypes. In our analysis patients were classified to lean or overweight/obese 
classes according to their BMI. In GSEA we found that miR-223 related AP-1 pathway was 
downregulated in obese phenotypes (FDR q-value < 0.25). In trajectory analysis we did not find 
differences between those groups that had gained or lost weight relatively from childhood to 
adulthood. 
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Discussion 
 
 
 
4.1 Overview 
 
 
MicroRNA-122 and miRNA-144 circulatory levels were associated with individual’s phenotype 
(lean/overweight or obese). A total of 22 miRNAs were associated with either or both BMI and 
WHRAT (independently of sex and age). MicroRNA-122 is known to be liver associated from 
previous studies performed by our group. MicroRNA-144 is potentially associated with impaired 
glucose tolerance. MicroRNA-223 targeted AP-1 pathway was down-regulated in overweight group 
in GSEA. 
 
MicroRNA-223 was positively correlated with BMI and has been linked to HDL in previous studies 
(Vickers, Palmisano, Shoucri, Shamburek, & Remaley, 2011b). MicroRNA-223 has been predicted 
to target cholesterol synthesis (Abente, Subramanian, Ramachandran, & Najafi-Shoushtari, 2015). 
MicroRNA-223 targeted AP-1 pathway was down-regulated in overweight class. Previous studies 
suggest that AP-1 activation would be down-regulated in liver tissue (Videla, 2010). AP-1 
transcription factor has been inflammation linked in previous studies (Latruffe et al., 2015). This 
study is the first to our knowledge that links miR-223 with AP-1 pathway. This finding could be 
utilized in the future but more studies are needed to demonstrate causality between miRNA-223 
expression and function of AP-1 pathway. 
 
4.2 MicroRNA-122 is liver associated 
 
 
MicroRNA-122 correlated with many liver variables (ASAT, ALAT, GT, apolipoproteins and 
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lipoprotein fractions etc.) showing it is clearly liver tissue specific miRNA. A previous refined study 
performed by our group shows its association with the liver (Raitoharju et al., 2016). It is very likely 
that obesity related fatty liver disease explains elevated miRNA-122 levels. 
 
4.3 MicroRNA-144-5p possibly associated with glucose intolerance 
 
 
Glucose intolerance plays a key role in obesity. MicroRNA-144-5p has been previously linked to 
obesity and its related diseases such as diabetes (Karolina et al., 2011). It is thought to regulate cell 
proliferation (usually by inhibiting) and tumorigenesis for example (Chen et al., 2015). Interestingly 
it was inversely regulated with BMI so according to our study it is possible that obesity leads to excess 
cell proliferation via miR-144-5p expression levels. 
The main disadvantage of this study is that results are mainly descriptive. In addition, we did not find 
differences in miRNA expression between those groups that had gained or lost weight from childhood 
to adulthood so miRNAs may be very variating in circulation. Hence, this study does not establish 
any support that dysregulated miRNA levels in childhood would lead to overweight in adulthood. 
Furthermore, it could be interesting to study miRNA expression levels from previous blood samples 
from study populations’ childhood. Some previous studies claim that miRNAs are unspecific in 
diseases as single miRNAs may target a number of genes. Results from previous miRNA and obesity 
related studies have been ambivalent and difficult to replicate. According to some studies 
methodological differences in circulatory miRNA profiling exacerbates comparison of results 
(Endzelins et al., 2016). Use of Caucasian study population limits generalization of our results to 
some extent. MicroRNA extractions from blood samples do not necessarily represent miRNA levels 
in tissues such as white adipose tissue. More studies are needed to establish possible mechanisms in 
which miR-223 acts in the potentially obesity related AP-1 pathway. 
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4.4 Conclusion 
 
 
In conclusion, according to our study miRNA expression levels vary depending on a person’s 
phenotype. MicroRNA-122 and miR-144 were related to a person’s phenotype in ANOVA analysis. 
MicroRNA-144 is potentially related with glucose metabolism and impaired glucose tolerance. In a 
novel finding we noticed, that MicroRNA-223 was related to previously obesity linked AP-1 pathway 
that was down-regulated in overweight group. More studies are required to obtain a causal relation 
of miRNAs in obesity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 
 
 
References 
 
 
 
Abente, E. J., Subramanian, M., Ramachandran, V., & Najafi-Shoushtari, S. H. (2015). MicroRNAs 
in obesity-associated disorders. Archives of Biochemistry and Biophysics, doi:S0003-
9861(15)30069-2 [pii] 
Arroyo, J. D., Chevillet, J. R., Kroh, E. M., Ruf, I. K., Pritchard, C. C., Gibson, D. F., . . . Tewari, 
M. (2011). Argonaute2 complexes carry a population of circulating microRNAs independent of 
vesicles in human plasma. Proceedings of the National Academy of Sciences of the United 
States of America, 108(12), 5003-5008. doi:10.1073/pnas.1019055108 [doi] 
Chen, S., Li, P., Li, J., Wang, Y., Du, Y., Chen, X., . . . Zhang, G. (2015). MiR-144 inhibits 
proliferation and induces apoptosis and autophagy in lung cancer cells by targeting TIGAR. 
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular 
Physiology, Biochemistry, and Pharmacology, 35(3), 997-1007. doi:10.1159/000369755 [doi] 
Cho, S., Jang, I., Jun, Y., Yoon, S., Ko, M., Kwon, Y., . . . Lee, S. (2013). MiRGator v3.0: A 
microRNA portal for deep sequencing, expression profiling and mRNA targeting. Nucleic 
Acids Research, 41(Database issue), D252-7. doi:10.1093/nar/gks1168 [doi] 
do Carmo, J. M., da Silva, A. A., Wang, Z., Fang, T., Aberdein, N., de Lara Rodriguez, C. E., & 
Hall, J. E. (2016). Obesity-induced hypertension: Brain signaling pathways. Current 
Hypertension Reports, 18(7), 58-016-0658-1. doi:10.1007/s11906-016-0658-1 [doi] 
Duclos, M. (2016). Osteoarthritis, obesity and type 2 diabetes: The weight of waist circumference. 
Annals of Physical and Rehabilitation Medicine, 59(3), 157-160. 
doi:10.1016/j.rehab.2016.04.002 [doi] 
Endzelins, E., Melne, V., Kalnina, Z., Lietuvietis, V., Riekstina, U., Llorente, A., & Line, A. (2016). 
Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: A 
systematic review. Molecular Cancer, 15(1), 41-016-0523-5. doi:10.1186/s12943-016-0523-5 
[doi] 
Friedman, R. C., Farh, K. K., Burge, C. B., & Bartel, D. P. (2009). Most mammalian mRNAs are 
conserved targets of microRNAs. Genome Research, 19(1), 92-105. doi:10.1101/gr.082701.108 
[doi] 
Grover, S. A., Kaouache, M., Rempel, P., Joseph, L., Dawes, M., Lau, D. C., & Lowensteyn, I. 
(2015). Years of life lost and healthy life-years lost from diabetes and cardiovascular disease in 
overweight and obese people: A modelling study. The Lancet.Diabetes & Endocrinology, 3(2), 
114-122. doi:10.1016/S2213-8587(14)70229-3 [doi] 
Hall, J. E., Crook, E. D., Jones, D. W., Wofford, M. R., & Dubbert, P. M. (2002). Mechanisms of 
obesity-associated cardiovascular and renal disease. The American Journal of the Medical 
Sciences, 324(3), 127-137. doi:S0002-9629(15)34401-3 [pii] 
Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z., & Hall, M. E. (2015). Obesity-induced 
hypertension: Interaction of neurohumoral and renal mechanisms. Circulation Research, 
116(6), 991-1006. doi:10.1161/CIRCRESAHA.116.305697 [doi] 
Karolina, D. S., Armugam, A., Tavintharan, S., Wong, M. T., Lim, S. C., Sum, C. F., & Jeyaseelan, 
K. (2011). MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin 
16 
 
 
receptor substrate 1 in type 2 diabetes mellitus. PloS One, 6(8), e22839. 
doi:10.1371/journal.pone.0022839 [doi] 
Lagos-Quintana, M., Rauhut, R., Lendeckel, W., & Tuschl, T. (2001). Identification of novel genes 
coding for small expressed RNAs. Science (New York, N.Y.), 294(5543), 853-858. 
doi:10.1126/science.1064921 [doi] 
Latruffe, N., Lancon, A., Frazzi, R., Aires, V., Delmas, D., Michaille, J. J., . . . Cherkaoui-Malki, M. 
(2015). Exploring new ways of regulation by resveratrol involving miRNAs, with emphasis on 
inflammation. Annals of the New York Academy of Sciences, 1348(1), 97-106. 
doi:10.1111/nyas.12819 [doi] 
Mazzarella, L. (2015). Why does obesity promote cancer? epidemiology, biology, and open 
questions. Ecancermedicalscience, 9, 554. doi:10.3332/ecancer.2015.554 [doi] 
Ovaskainen, M. L., Tapanainen, H., Laatikainen, T., Mannisto, S., Heinonen, H., & Vartiainen, E. 
(2015). Perceived health-related self-efficacy associated with BMI in adults in a population-
based survey. Scandinavian Journal of Public Health, 43(2), 197-203. 
doi:10.1177/1403494814566263 [doi] 
Parhofer, K. G. (2015). Interaction between glucose and lipid metabolism: More than diabetic 
dyslipidemia. Diabetes & Metabolism Journal, 39(5), 353-362. doi:10.4093/dmj.2015.39.5.353 
[doi] 
Raitakari, O. T., Juonala, M., Ronnemaa, T., Keltikangas-Jarvinen, L., Rasanen, L., Pietikainen, M., 
. . . Viikari, J. S. (2008). Cohort profile: The cardiovascular risk in young finns study. 
International Journal of Epidemiology, 37(6), 1220-1226. doi:10.1093/ije/dym225 [doi] 
Raitoharju, E. (2014). MicroRNAs in the etiology and pathophysiology of atherosclerosis 
(ACADEMIC DISSERTATION). Retrieved from http://tampub.uta.fi 
Raitoharju, E., Seppala, I., Lyytikainen, L. P., Viikari, J., Ala-Korpela, M., Soininen, P., . . . 
Lehtimaki, T. (2016). Blood hsa-miR-122-5p and hsa-miR-885-5p levels associate with fatty 
liver and related lipoprotein metabolism-the young finns study. Scientific Reports, 6, 38262. 
doi:10.1038/srep38262 [doi] 
Raitoharju, E., Seppala, I., Oksala, N., Lyytikainen, L. P., Raitakari, O., Viikari, J., . . . Lehtimaki, T. 
(2014). Blood microRNA profile associates with the levels of serum lipids and metabolites 
associated with glucose metabolism and insulin resistance and pinpoints pathways underlying 
metabolic syndrome: The cardiovascular risk in young finns study. Molecular and Cellular 
Endocrinology, 391(1-2), 41-49. doi:10.1016/j.mce.2014.04.013 [doi] 
Suomela, E., Oikonen, M., Virtanen, J., Parkkola, R., Jokinen, E., Laitinen, T., . . . Raitakari, O. T. 
(2014). Prevalence and determinants of fatty liver in normal-weight and overweight young 
adults. the cardiovascular risk in young finns study. Annals of Medicine, , 1-7. 
doi:10.3109/07853890.2014.966752 [doi] 
Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J. J., & Lotvall, J. O. (2007). Exosome-
mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange 
between cells. Nature Cell Biology, 9(6), 654-659. doi:ncb1596 [pii] 
Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D., & Remaley, A. T. (2011a). 
MicroRNAs are transported in plasma and delivered to recipient cells by high-density 
lipoproteins. Nature Cell Biology, 13(4), 423-433. doi:10.1038/ncb2210 [doi] 
Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D., & Remaley, A. T. (2011b). 
MicroRNAs are transported in plasma and delivered to recipient cells by high-density 
lipoproteins. Nature Cell Biology, 13(4), 423-433. doi:10.1038/ncb2210 [doi] 
17 
 
 
Videla, L. A. (2010). Liver NF-kappaB and AP-1 activation and PPAR-alpha expression are 
negatively correlated in obese patients: Pro-inflammatory implications. Clinical Nutrition 
(Edinburgh, Scotland), 29(5), 687-688. doi:10.1016/j.clnu.2010.03.006 [doi] 
Vucenik, I., & Stains, J. P. (2012). Obesity and cancer risk: Evidence, mechanisms, and 
recommendations. Annals of the New York Academy of Sciences, 1271, 37-43. 
doi:10.1111/j.1749-6632.2012.06750.x [doi] 
Wang, Y., Beydoun, M. A., Liang, L., Caballero, B., & Kumanyika, S. K. (2008). Will all americans 
become overweight or obese? estimating the progression and cost of the US obesity epidemic. 
Obesity (Silver Spring, Md.), 16(10), 2323-2330. doi:10.1038/oby.2008.351 [doi] 
Zimmet, P., Alberti, K. G., & Shaw, J. (2001). Global and societal implications of the diabetes 
epidemic. Nature, 414(6865), 782-787. doi:10.1038/414782a [doi] 
  
 
